{"id":250810,"date":"2025-06-16T00:00:00","date_gmt":"2025-06-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcg0017-biopharma-multiple-sclerosis-epidemiology-mature-markets\/"},"modified":"2026-04-14T10:12:23","modified_gmt":"2026-04-14T10:12:23","slug":"epidcg0017-biopharma-multiple-sclerosis-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0017-biopharma-multiple-sclerosis-epidemiology-mature-markets\/","title":{"rendered":"Multiple Sclerosis &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of multiple sclerosis (<abbr title=\"multiple sclerosis\">MS<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"multiple sclerosis\">MS<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p><span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"8\" data-last-change-time=\"1756454496823\" data-time=\"1756454496823\" data-userid=\"63125\" data-username=\"Megha\">P<\/span>atient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"multiple sclerosis\">MS<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"multiple sclerosis\">MS<\/abbr>, how many in each country in the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"multiple sclerosis\">MS<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"multiple sclerosis\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 16 <abbr title=\"multiple sclerosis\">MS<\/abbr> patient populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed <abbr title=\"multiple sclerosis\">MS<\/abbr> prevalent cases<\/li>\n<li>Diagnosed <abbr title=\"relapsing-remitting multiple sclerosis\">RR-MS<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed <abbr title=\"secondary-progressive multiple sclerosis\">SP-MS<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed <abbr title=\"clinically isolated syndrome\">CIS<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed <abbr title=\"multiple sclerosis\">MS<\/abbr> incident cases<\/li>\n<li>Diagnosed <abbr title=\"relapsing-remitting multiple sclerosis\">RR-<\/abbr><abbr title=\"relapsing-remitting multiple sclerosis\">MS<\/abbr> incident cases.<\/li>\n<li>Diagnosed <abbr title=\"primary-progressive multiple sclerosis\">PP-<\/abbr><abbr title=\"primary-progressive multiple sclerosis\">MS<\/abbr> incident cases.<\/li>\n<li>Diagnosed <abbr title=\"clinically isolated syndrome\">CIS<\/abbr> incident cases.<\/li>\n<li>Diagnosed drug-treated <abbr title=\"multiple sclerosis\">MS<\/abbr> prevalent cases<\/li>\n<li>Diagnosed drug-treated <abbr title=\"relapsing-remitting multiple sclerosis\">RR-MS<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed drug-treated <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed drug-treated <abbr title=\"secondary-progressive multiple sclerosis\">SP-MS<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed drug-treated <abbr title=\"clinically isolated syndrome\">CIS<\/abbr> prevalent cases.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250810","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250810\/revisions"}],"predecessor-version":[{"id":543398,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250810\/revisions\/543398"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}